X4 Pharmaceuticals (XFOR) Shares Outstanding (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Shares Outstanding (Entity) for 10 consecutive years, with $126.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 1487.25% year-over-year to $126.3 million; the trailing twelve-month figure through Jun 2026 stood at $126.3 million (up 1487.25% YoY), and the FY2025 full-year result was $42.3 million, up 642.21% from the prior year.
• Shares Outstanding (Entity) steadied at $126.3 million in Q2 2026 per XFOR's latest filing, from $126.3 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $200.4 million in Q2 2024 and bottomed at $5.6 million in Q3 2024.
• Historically, Shares Outstanding (Entity) has averaged $88.2 million across 5 years, with a median of $66.1 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) tumbled 97.11% in 2025, then soared 2081.63% in 2026.
• Over 5 years, Shares Outstanding (Entity) stood at $63.5 million in 2022, then soared by 179.91% to $177.8 million in 2023, then plunged by 96.8% to $5.7 million in 2024, then surged by 642.21% to $42.3 million in 2025, then soared by 198.74% to $126.3 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $126.3 million, $126.3 million, and $42.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.